STADA and Alvotech receive positive CHMP opinion for Europe's first ustekinumab biosimilar to Stelara - Alvotech (NASDAQ:ALVO)

CHMP positive opinion in the European Economic Area for first biosimilar to Stelara, a biologic therapy within gastroenterology, dermatology and rheumatologyPositive CHMP opinion for Uzpruvo biosimilar is based on

Related Keywords

Norway ,South Korea ,United Kingdom ,Bangladesh ,Vietnam ,Republic Of ,Hong Kong ,Bad Vilbel ,Hessen ,Germany ,Israel ,Malaysia ,United States ,Indonesia ,Thailand ,Japan ,Yangtze River ,China General ,China ,New Zealand ,Pakistan ,Iceland ,Cambodia ,Reykjavik ,C10 ,Taiwan ,India ,Liechtenstein ,Singapore ,Philippines ,Saval Latin America ,Bryan Kim ,Joseph Mcclellan ,Robert Wessman ,Africa ,Linkedin ,Lotus Pharmaceuticals Co Ltd ,European Medicines Agency ,European Union ,Fuji Pharma Co Ltd Japan ,Oaktree Acquisition Corp ,Teva Pharmaceutical Industries Ltd ,Pharma Corporation Canada ,Teva Pharmaceuticals ,Global Communications ,Committee For Medicinal Products Human Use ,Alvotech Holdings ,Yangtze River Pharmaceutical Group Co Ltd ,Kamada Ltd ,European Economic Area ,Medicinal Products ,Human Use ,Specialty Head ,Chief Scientific Officer Joseph Mcclellan ,South America ,Teva Pharmaceutical Industries ,Advanz Pharma ,Cipla Med Pro ,Yangtze River Pharmaceutical ,Middle East ,North Africa ,Abdi Ibrahim ,Mega Labs ,Latin America ,Private Securities Litigation Reform Act ,Oaktree Acquisition ,Note Regarding Forward Looking ,Creditor Relations ,Investor Relations ,